| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ENTPD1 |
| Uniprot No | P49961 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-510aa |
| 氨基酸序列 | MEDTKESNVKTFCSKNILAILGFSSIIAVIALLAVGLTQNKALPENVKYG IVLDAGSSHTSLYIYKWPAEKENDTGVVHQVEECRVKGPGISKFVQKVNE IGIYLTDCMERAREVIPRSQHQETPVYLGATAGMRLLRMESEELADRVLD VVERSLSNYPFDFQGARIITGQEEGAYGWITINYLLGKFSQKTRWFSIVP YETNNQETFGALDLGGASTQVTFVPQNQTIESPDNALQFRLYGKDYNVYT HSFLCYGKDQALWQKLAKDIQVASNEILRDPCFHPGYKKVVNVSDLYKTP CTKRFEMTLPFQQFEIQGIGNYQQCHQSILELFNTSYCPYSQCAFNGIFL PPLQGDFGAFSAFYFVMKFLNLTSEKVSQEKVTEMMKKFCAQPWEEIKTS YAGVKEKYLSEYCFSGTYILSLLLQGYHFTADSWEHIHFIGKIQGSDAGW TLGYMLNLTNMIPAEQPLSTPLSHSTYVFLMVLFSLVLFTVAIIGLLIFH KPSYFWKDMV |
| 预测分子量 | 82 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ENTPD1重组蛋白的3篇代表性文献摘要示例：
1. **《Recombinant human CD39/ENTPD1 inhibits platelet aggregation in vitro and promotes thrombus resolution in vivo》**
- 作者：H. L. Thompson et al. (2020)
- 摘要：研究通过重组表达人源ENTPD1蛋白，验证其体外水解ATP/ADP的能力及抑制血小板聚集的作用，并在血栓模型中证实其促进血栓溶解的效果。
2. **《Structural basis of ENTPD1-mediated extracellular nucleotide metabolism》**
- 作者：K. Yamada et al. (2018)
- 摘要：解析了重组ENTPD1蛋白的晶体结构，阐明其催化活性位点及底物特异性机制，为开发靶向该酶的调节剂提供结构依据。
3. **《CD39 recombinant protein enhances antitumor immunity by reducing adenosine-mediated immunosuppression》**
- 作者：M. L. Silva & J. P. Allard (2021)
- 摘要：在小鼠肿瘤模型中，重组ENTPD1蛋白通过降解免疫抑制性腺苷，增强T细胞抗肿瘤活性，证明其与免疫检查点疗法的协同效应。
(注：以上为模拟摘要，实际文献需通过数据库如PubMed检索。)
ENTPD1 (Ectonucleoside Triphosphate Diphosphohydrolase 1), also known as CD39. is a membrane-bound glycoprotein belonging to the ectonucleoside triphosphate diphosphohydrolase family. It plays a critical role in purinergic signaling by hydrolyzing extracellular ATP and ADP into AMP, which is subsequently converted to adenosine by CD73 (ecto-5'-nucleotidase). This enzymatic activity regulates the balance between pro-inflammatory ATP and immunosuppressive adenosine, making ENTPD1 a pivotal modulator of immune responses and vascular homeostasis.
Structurally, ENTPD1 contains four conserved apyrase domains and two transmembrane regions, anchoring it to the cell surface. It is expressed on immune cells (e.g., regulatory T cells, dendritic cells), endothelial cells, and certain tumor cells. Dysregulation of ENTPD1 is implicated in pathological conditions such as chronic inflammation, autoimmune diseases, and cancer. In the tumor microenvironment, ENTPD1 overexpression by cancer or stromal cells promotes adenosine accumulation, suppressing anti-tumor immunity and facilitating immune evasion.
Recombinant ENTPD1 protein is engineered in vitro using expression systems (e.g., mammalian or insect cells) to produce soluble, functional forms for research and therapeutic applications. It is widely used to study enzymatic kinetics, ligand interactions, and signaling pathways in immune-oncology. Additionally, ENTPD1-targeting therapies, including inhibitory antibodies or recombinant proteins, are being explored to block adenosine generation, thereby enhancing anti-cancer immune responses. Recombinant ENTPD1 also serves as a tool for developing diagnostic assays and screening small-molecule inhibitors. Its dual role in inflammation and immunity underscores its potential as a biomarker and therapeutic target in diseases driven by dysregulated purinergic signaling.
×
